Tirofiban after successful clot removal for stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving a medication called tirofiban directly into the artery (intra-arterially) after a successful clot removal can improve recovery after a stroke. Tirofiban helps prevent new clots from forming, which may reduce the chance of another stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your stroke treatment (procedure to remove the clot) must have started within 24 hours of when you were last known to be well.
- The blockage must be in a large artery in the front part of the brain (like the internal carotid or middle cerebral artery).
- Your stroke symptoms must be moderate to severe but not extremely mild or extremely severe (measured by a stroke severity score).
- Before the stroke, you must have been able to live independently (no significant disability).
- After the procedure to remove the clot, the artery must be fully reopened (complete recanalization).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial tests whether adding a medicine called tirofiban (which helps prevent blood clots) after standard stroke treatment can improve recovery in people who had a stroke due to a blocked large artery in the brain. It is for people who already received a clot-busting drug and a mechanical clot removal procedure, and who have not fully recovered.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This study tests whether giving the blood-thinning drug tirofiban for a shorter or longer time after standard clot-busting treatment improves recovery from a stroke. It aims to find the best duration to prevent further damage while avoiding side effects.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.